Pharmatech Associates, a USP company’s Post

National policy on Medical Devices sector development : Dt : 28.4.2023. 1. Cabinet approves policy on 25.4.2023. 2. A highly potential health care segment for investments where country is still dependent on large imports at present. 3. Usage of medical devices in the country is rapidly growing . 4. With policy support , sector likely to grow from present $11 Bn ( approximately, 90,000 Cr) to $50 Bn in next five years. - Govt has already is already encouraging this segment for import substitution / localisation by granting some projects under PLI scheme. - Under the PLI scheme for Medical Devices, till now, a total of 26 projects have been approved, with a committed investment of Rs.1206 Cr . - Extended support for setting up 4 Medical devices Parks. - Under the PLI scheme, total of 14 projects producing 37 products have been commissioned . The Govt’s intention is very clear but policy appears to be not well prepared! Our Pharma sector has grown well with the first National Drug policy announcement in 1978 based on an extremely good exercise involving huge data collection and recommendations made by the most famous Hathi Committee. Our enterprenuers should not loose the opportunity for investments in this sector. *****

Driving BioPharma value, evidence, and access in Bulgaria >> https://lnkd.in/d8iAY4sc This update focuses on value, evidence, and access in Bulgaria and explores: - Reimbursement pathways for medicinal products - National access options - Reimbursement entry requirements and discount negotiation process - Stakeholder mapping and deadlines for medical devices Read the update >> https://lnkd.in/d8iAY4sc We were pleased to partner with HTA Ltd. on this update for value, evidence, and access in Bulgaria. Learn more about HTA Ltd >> https://lnkd.in/dspdp_M5 #HEOR #MarketAccess

Driving BioPharma value, evidence, and access in Bulgaria >> https://lnkd.in/d8iAY4sc This update focuses on value, evidence, and access in Bulgaria and explores: - Reimbursement pathways for medicinal products - National access options - Reimbursement entry requirements and discount negotiation process - Stakeholder mapping and deadlines for medical devices Read the update >> https://lnkd.in/d8iAY4sc We were pleased to partner with HTA Ltd. on this update for value, evidence, and access in Bulgaria. Learn more about HTA Ltd >> https://lnkd.in/dspdp_M5 #HEOR #MarketAccess

Similar but different: the importance of medical device combination product differentiation Emergo by UL's human factors specialists share key considerations for combination product differentiation. Read more here: https://s.ul.com/3UqrFvn #medicaldevice #regulatoryaffairs #insight #medtech #healthtech #biotech #humanfactors #weareULSolutions

"Clinical Trials are scientific studies conducted to evaluate the safety & effectiveness of medical treatments, drugs, therapies, or devices in humans. The goal is to provide evidence-based medical interventions that enhance patient care, while rigorous controls & ethical considerations ensure participant well-being." Source: https://bit.ly/3Tgk6H0 #TridentClinical #Kimberley #ClinicalTrials #MedicalResearch #PatientSafety #TreatmentTesting #InformedConsent #ResearchStudy #MedicalAdvancement #Healthcare #ResearchEthics #PhasesOfTrials #medicalinnovation #SafetyMonitoring #PatientCare #ScientificStudy #DataAnalysis #MedicalScience #ClinicalResearch

In this episode, Dr Sanjay Kalra discusses the pivotal role of the pharmaceutical industry in fostering a healthier India with industry expert Mr. Makarand Kulkarni. They highlight the insights and challenges and explore how this dynamic sector drives medical advancements, promotes wellness, and contributes to a more robust healthcare ecosystem, ultimately paving the way for a healthier nation. To watch the full episode and gain insights, please follow the provided link: https://lnkd.in/d_nU_QpY #pharmatalks #pharmatalksindia #medical #pharmaceuticalindustry #pharmaindustry #medtalks #ijcpgroup

In this episode, Dr Sanjay Kalra discusses the pivotal role of the pharmaceutical industry in fostering a healthier India with industry expert Mr. Makarand Kulkarni. They highlight the insights and challenges and explore how this dynamic sector drives medical advancements, promotes wellness, and contributes to a more robust healthcare ecosystem, ultimately paving the way for a healthier nation. To watch the full episode and gain insights, please follow the provided link: https://lnkd.in/d_nU_QpY #pharmatalks #pharmatalksindia #medical #pharmaceuticalindustry #pharmaindustry #medtalks #ijcpgroup

Research shows plans for Congress to expand #IRA drug price controls could cost the U.S. 1.2 million biopharmaceutical industry jobs across all 50 states. Read more about VitalTransformation’s new study: https://lnkd.in/e9PcVphU We Work For Health

A little bit worrying this :/ Biosimilars have revolutionised the healthcare industry since their adoption in 2006, the main effect being that drugs are cheaper and more accessible. Reports like this suggest that there is a problem in the process, thereby making the products less accessible. Clearly the end goal is reduce the costs in getting them to the market, but what's the solution? Let me know your thoughts. #biosimilars

FDA-Approved Drugs: Monthly Edition 💊🌟 Stay informed with the latest breakthroughs in medicine! This month, we're spotlighting the newest FDA-approved drugs revolutionizing healthcare. From innovative treatments to life-changing therapies, these advancements are set to impact patient care significantly. Keep up with the cutting-edge developments and discover how these new approvals can benefit you. . . . . . . #FDAApproved #PharmaceuticalIndustry #HealthcareInnovation #MedicalBreakthroughs #DrugDevelopment #ClinicalResearch #PharmaNews #MedicareAdvancements #HealthUpdates #MedicalScience #HealthcareTechnology #TheLotusBiotech #TLB